JPRN-UMIN000000570
Unknown
N/A
Follow-up study for localized prostate cancer treated by hormonal therapy or radical prostatectomy. - J-CaP IS-1 study
J-CaP study group0 sites2,000 target enrollmentDecember 30, 2006
ConditionsProstate cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostate cancer
- Sponsor
- J-CaP study group
- Enrollment
- 2000
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
PROstate cancer follow-up care in Secondary and Primary hEalth Care: PROSPEC study.Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.NL-OMON24717Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands390
Recruiting
N/A
Focal therapy for locally recurrent prostate cancerprostate cancerJPRN-UMIN000038761Tokyo Medical and Dental University100
Active, Not Recruiting
Phase 1
Study on patients with recurrence of prostate cancer with PET/MRRadically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)MedDRA version: 21.1Level: LLTClassification code 10026389Term: Malignant neoplasm of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001036-21-ITOSPEDALE SAN RAFFAELE60
Not Yet Recruiting
N/A
Focal therapy of recurrent prostate cancer after external beam radiation therapy using mpMRI/TRUS-guided high intensity focused ultrasound (HIFU) technology (FOXPRO_RAD) – an initial pilot studyC61Malignant neoplasm of prostateDRKS00009020Klinik für Urologie, Universitätsmedizin Mannheim15
Not Yet Recruiting
N/A
PROSPEC study; PROstate cancer follow-up care in Secondary and Primary hEalth CareNL-OMON48798ederlands Kanker Instituut390